Given the common occurrence of NF1 mutation in BRAF-WT melanoma, which renders patients unsuitable for BRAF targeting, it is crucial to thoroughly understand NF1-mutated melanoma to guide the development of appropriate treatments for this aggressive subtype. The gene discussed is BRAF; the disease is melanoma.